• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Warby Parker Inc. (Amendment)

    2/14/24 10:04:37 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care
    Get the next $WRBY alert in real time by email
    SC 13G/A 1 wrby13gadec23.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) WARBY PARKER INC-CLASS A (Name of Issuer) COMMON STOCK (Title of Class of Securities) 93403J106 (CUSIP NUMBER) December 31, 2023 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1. Name of Reporting Person T. Rowe Price Investment Management, Inc. 85-4328500 2. Check the Appropriate Box if a Member of a Group NOT APPLICABLE 3. SEC Use Only 4. Citizenship or Place of Organization Maryland Number of Shares Beneficially Owned by Each Reporting Person With 5. Sole Voting Power* 1,555,027 6. Shared Voting Power* 0 7. Sole Dispositive Power* 5,076,485 8. Shared Dispositive Power 0 9. Aggregate Amount Beneficially Owned by Each Reporting Person 5,076,485 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares NOT APPLICABLE 11. Percent of Class Represented by Amount in Row 9 5.2% 12. Type of Reporting Person IA *Any shares reported in Items 5 and 6 are also reported in Item 7. Item 1(a) Name of Issuer: WARBY PARKER INC-CLASS A Item 1(b) Address of Issuer's Principal Executive Offices: 233 SPRING STREET, 6TH FLOOR EAST, NEW YORK, NEW YORK 10013 Item 2(a) Name of Person(s) Filing: (1) T. Rowe Price Investment Management, Inc. (Price Investment Management) Item 2(b) Address of Principal Business Office: 101 E. Pratt Street, Baltimore, MD 21201 Item 2(c) Citizenship or Place of Organization: (1) Maryland Item 2(d) Title of Class of Securities: COMMON STOCK Item 2(e) Cusip Number: 93403J106 Item 3: The person filing this Schedule 13G is an: X Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940 Item 4: Reference is made to Items 5-11 on the preceding pages of this Schedule 13G. Item 5: Ownership of Five Percent or Less of a Class Not Applicable Item 6: Ownership of More than Five Percent on Behalf of Another Person (1) Price Investment Management does not serve as custodian of the assets of any of its clients; accordingly, in each instance only the client or the client's custodian or trustee bank has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. The ultimate power to direct the receipt of dividends paid with respect to, and the proceeds from the sale of, such securities, is vested in the individual and institutional clients which Price Investment Management serves as investment adviser. Any and all discretionary authority which has been delegated to Price Investment Management may be revoked in whole or in part at any time. Except as may be indicated if this is a joint filing with one of the registered investment companies sponsored by Price Investment Management which it also serves as investment adviser ("T. Rowe Price Funds"), not more than 5% of the class of such securities is owned by any one client subject to the investment advice of Price Investment Management. Item 7: Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. Not Applicable Item 8: Identification and Classification of Members of the Group Not Applicable Item 9: Notice of Dissolution of Group Not Applicable Item 10: Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. T. Rowe Price Investment Management, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. T. Rowe Price Investment Management, Inc. Date: February 14, 2024 Signature: /s/ Armando Capasso Name & Title: Armando Capasso, Vice President 12/31/2023
    Get the next $WRBY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $WRBY

    DatePrice TargetRatingAnalyst
    4/30/2025$17.00Sell → Neutral
    Citigroup
    4/17/2025$27.00Hold → Buy
    Loop Capital
    2/28/2025$28.00 → $30.00Outperform
    Telsey Advisory Group
    2/25/2025$26.00Neutral
    ROTH MKM
    2/5/2025$19.00 → $23.00Neutral → Sell
    Citigroup
    1/17/2025$23.00Outperform → In-line
    Evercore ISI
    11/19/2024$22.00 → $26.00Outperform
    Telsey Advisory Group
    11/8/2024$19.00 → $22.00Outperform
    Telsey Advisory Group
    More analyst ratings

    $WRBY
    Leadership Updates

    Live Leadership Updates

    See more
    • Warby Parker appoints Ronald A. Williams as Lead Director and welcomes Bradley E. Singer to Board of Directors

      Warby Parker Inc. (NYSE:WRBY) ("Warby Parker" or the "Company") announced today the appointment of Ron Williams as Lead Director. "Ron's deep expertise in transformational leadership is helping Warby Parker lead the way in making the optical industry more customer and patient friendly. Our shareholders and our team are lucky to have such an exceptional and experienced leader as our first Lead Director," said Neil Blumenthal, co-Founder and co-CEO. The Company has also appointed a new independent director, Brad Singer, to its board of directors. Mr. Singer's appointment is effective today, August 1, 2024. "Brad brings a wealth of experience as a dynamic operator and investor," said Dav

      8/1/24 4:15:00 PM ET
      $WRBY
      Ophthalmic Goods
      Health Care

    $WRBY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Singer Bradley E bought $965,750 worth of shares (75,000 units at $12.88) (SEC Form 4)

      4 - Warby Parker Inc. (0001504776) (Issuer)

      8/14/24 4:52:02 PM ET
      $WRBY
      Ophthalmic Goods
      Health Care

    $WRBY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Cutler Joel E disposed of 5,656,571 shares (SEC Form 4)

      4 - Warby Parker Inc. (0001504776) (Issuer)

      3/18/25 9:52:05 PM ET
      $WRBY
      Ophthalmic Goods
      Health Care
    • Chief Financial Officer Miller Steven Clive sold $274,808 worth of shares (11,684 units at $23.52), was granted 15,128 shares, covered exercise/tax liability with 6,321 shares and converted options into 27,731 shares, increasing direct ownership by 14% to 204,727 units (SEC Form 4)

      4 - Warby Parker Inc. (0001504776) (Issuer)

      3/6/25 6:02:10 AM ET
      $WRBY
      Ophthalmic Goods
      Health Care
    • Co-Chief Executive Officer Gilboa David Abraham converted options into 3,271 shares, sold $4,772,513 worth of shares (202,968 units at $23.51), was granted 23,250 shares, covered exercise/tax liability with 12,858 shares and converted options into 201,088 shares, increasing direct ownership by 96% to 24,089 units (SEC Form 4)

      4 - Warby Parker Inc. (0001504776) (Issuer)

      3/5/25 9:57:41 PM ET
      $WRBY
      Ophthalmic Goods
      Health Care

    $WRBY
    SEC Filings

    See more
    • SEC Form 10-Q filed by Warby Parker Inc.

      10-Q - Warby Parker Inc. (0001504776) (Filer)

      5/8/25 5:10:13 PM ET
      $WRBY
      Ophthalmic Goods
      Health Care
    • Warby Parker Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Warby Parker Inc. (0001504776) (Filer)

      5/8/25 6:46:05 AM ET
      $WRBY
      Ophthalmic Goods
      Health Care
    • SEC Form DEFA14A filed by Warby Parker Inc.

      DEFA14A - Warby Parker Inc. (0001504776) (Filer)

      5/6/25 5:07:56 PM ET
      $WRBY
      Ophthalmic Goods
      Health Care

    $WRBY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Warby Parker Announces First Quarter 2025 Results

      Net revenue increased 12% year over year to $224 million Active Customers increased 9% on a trailing 12-month basis Warby Parker Inc. (NYSE:WRBY) ("Warby Parker" or the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced financial results for the first quarter ended March 31, 2025. "Our team delivered a strong start to 2025. We opened 11 net new stores, exceeded profitability expectations, drove the highest e-commerce growth we've seen since 2021, and delivered our seventh consecutive quarter of accelerating active customer growth," shared Co-Founder and Co-CEO Neil Blumenthal. "Looking to the rest of the year, we'll leverage our diversified suppl

      5/8/25 6:45:00 AM ET
      $WRBY
      Ophthalmic Goods
      Health Care
    • Warby Parker to Announce First Quarter 2025 Financial Results on May 8, 2025

      Warby Parker Inc. (NYSE:WRBY) (the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced that its financial results for the first quarter ended March 31, 2025 will be released before market open on May 8, 2025. In addition, the Company will discuss its results and business outlook during a live conference call and webcast at 8:00 a.m. Eastern Time. The conference call can be accessed by dialing 833-470-1428 from the U.S. or 404-975-4839 from international locations. The conference passcode is 020310. A live webcast of the conference call will be available on the investors section of the Company's website at investors.warbyparker.com where presentation

      4/17/25 4:05:00 PM ET
      $WRBY
      Ophthalmic Goods
      Health Care
    • Target and Warby Parker Team Up to Bring Stylish, Affordable Eyewear to More Consumers

      New Warby Parker at Target shop-in-shops will offer guests designer-quality eyewear as well as contacts and eye exams Five shop-in-shops will debut in 2025 with plans to open more in the years aheadMINNEAPOLIS and NEW YORK, Feb. 27, 2025 /PRNewswire/ -- Target Corporation (NYSE:TGT) and Warby Parker (NYSE:WRBY) are partnering to bring designer-quality, affordable eyewear to even more consumers through the retailer's newest shop-in-shop, Warby Parker at Target. Each Warby Parker at Target shop-in-shop will offer products and services — including glasses, sunglasses, contacts, e

      2/27/25 7:15:00 AM ET
      $TGT
      $WRBY
      Department/Specialty Retail Stores
      Consumer Discretionary
      Ophthalmic Goods
      Health Care

    $WRBY
    Financials

    Live finance-specific insights

    See more
    • Warby Parker Announces First Quarter 2025 Results

      Net revenue increased 12% year over year to $224 million Active Customers increased 9% on a trailing 12-month basis Warby Parker Inc. (NYSE:WRBY) ("Warby Parker" or the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced financial results for the first quarter ended March 31, 2025. "Our team delivered a strong start to 2025. We opened 11 net new stores, exceeded profitability expectations, drove the highest e-commerce growth we've seen since 2021, and delivered our seventh consecutive quarter of accelerating active customer growth," shared Co-Founder and Co-CEO Neil Blumenthal. "Looking to the rest of the year, we'll leverage our diversified suppl

      5/8/25 6:45:00 AM ET
      $WRBY
      Ophthalmic Goods
      Health Care
    • Warby Parker to Announce First Quarter 2025 Financial Results on May 8, 2025

      Warby Parker Inc. (NYSE:WRBY) (the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced that its financial results for the first quarter ended March 31, 2025 will be released before market open on May 8, 2025. In addition, the Company will discuss its results and business outlook during a live conference call and webcast at 8:00 a.m. Eastern Time. The conference call can be accessed by dialing 833-470-1428 from the U.S. or 404-975-4839 from international locations. The conference passcode is 020310. A live webcast of the conference call will be available on the investors section of the Company's website at investors.warbyparker.com where presentation

      4/17/25 4:05:00 PM ET
      $WRBY
      Ophthalmic Goods
      Health Care
    • Warby Parker Announces Fourth Quarter and Full Year 2024 Results

      Q4 net revenue increased 17.8% year over year; 2024 net revenue increased 15.2% year over year Active Customers increased 7.8% on a trailing 12-month basis Warby Parker Inc. (NYSE:WRBY) ("Warby Parker" or the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced financial results for the fourth quarter and full year ended December 31, 2024. "Our strong 2024 results highlight the power of Warby Parker's brand and unmatched value proposition combined with our team's high-quality execution. We delivered on our ambitious goals to accelerate revenue growth, customer growth and glasses growth, all while maintaining operational discipline and expanding p

      2/27/25 6:45:00 AM ET
      $TGT
      $WRBY
      Department/Specialty Retail Stores
      Consumer Discretionary
      Ophthalmic Goods
      Health Care

    $WRBY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Warby Parker upgraded by Citigroup with a new price target

      Citigroup upgraded Warby Parker from Sell to Neutral and set a new price target of $17.00

      4/30/25 1:18:55 PM ET
      $WRBY
      Ophthalmic Goods
      Health Care
    • Warby Parker upgraded by Loop Capital with a new price target

      Loop Capital upgraded Warby Parker from Hold to Buy and set a new price target of $27.00

      4/17/25 8:27:42 AM ET
      $WRBY
      Ophthalmic Goods
      Health Care
    • Telsey Advisory Group reiterated coverage on Warby Parker with a new price target

      Telsey Advisory Group reiterated coverage of Warby Parker with a rating of Outperform and set a new price target of $30.00 from $28.00 previously

      2/28/25 8:48:26 AM ET
      $WRBY
      Ophthalmic Goods
      Health Care

    $WRBY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Warby Parker Inc.

      SC 13G/A - Warby Parker Inc. (0001504776) (Subject)

      11/14/24 5:08:23 PM ET
      $WRBY
      Ophthalmic Goods
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Warby Parker Inc.

      SC 13G/A - Warby Parker Inc. (0001504776) (Subject)

      11/14/24 1:30:16 PM ET
      $WRBY
      Ophthalmic Goods
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Warby Parker Inc.

      SC 13G/A - Warby Parker Inc. (0001504776) (Subject)

      11/12/24 10:40:28 AM ET
      $WRBY
      Ophthalmic Goods
      Health Care